The Association of Lipids and Novel Non-statin Lipid-lowering Drug Target with Osteoporosis: Evidence from Genetic Correlations and Mendelian Randomization

Overview

Journal BMC Musculoskelet Disord

Publisher Biomed Central

Date 2025 Feb 1

PMID 39893413

Authors

Qingcong Zheng

Rongjie Lin

Du Wang

Rongsheng Chen

Weihong Xu

Affiliations

Soon will be listed here.

Abstract

Background: It remains controversial whether lipids affect osteoporosis (OP) or bone mineral density (BMD), and causality has not been established. This study aimed to investigate the genetic associations between lipids, novel non-statin lipid-lowering drug target genes, and OP and BMD.

Methods: Mendelian randomization (MR) method was used to explore the genetic associations between 179 lipid species and OP, BMD. Drug-target MR analysis was used to explore the causal associations between angiopoietin-like protein 3 (ANGPTL3) and apolipoprotein C3 (APOC3) inhibitors on BMD.

Results: The IVW results with Bonferroni correction indicated that triglyceride (TG) (51:3) (OR = 1.0029; 95% CI: 1.0014-1.0045; P = 0.0002) and TG (56:6) (OR = 1.0021; 95% CI: 1.0008-1.0033; P = 0.0011) were associated with an increased risk of OP; TG (51:2) (OR = 0.9543; 95% CI: 0.9148-0.9954; P = 0.0298) was associated with decreased BMD; and ANGPTL3 inhibitor (OR = 1.1342; 95% CI: 1.0393-1.2290; P = 0.0093) and APOC3 inhibitor (OR = 1.0506; 95% CI: 1.0155-1.0857; P = 0.0058) was associated with increased BMD.

Conclusions: MR analysis indicated causal associations between genetically predicted TGs and OP and BMD. Drug-target MR analysis showed that ANGPTL3 and APOC3 have the potential to serve as novel non-statin lipid-lowering drug targets to treat or prevent OP.

References

Kim J, Ha J, Jeong C, Lee J, Lim Y, Jo K . Bone mineral density and lipid profiles in older adults: a nationwide cross-sectional study. Osteoporos Int. 2022; 34(1):119-128. DOI: 10.1007/s00198-022-06571-z. View

Wang B, Wang H, Li Y, Song L . Lipid metabolism within the bone micro-environment is closely associated with bone metabolism in physiological and pathophysiological stages. Lipids Health Dis. 2022; 21(1):5. PMC: 8742318. DOI: 10.1186/s12944-021-01615-5. View

Muruganandan S, Ionescu A, Sinal C . At the Crossroads of the Adipocyte and Osteoclast Differentiation Programs: Future Therapeutic Perspectives. Int J Mol Sci. 2020; 21(7). PMC: 7177886. DOI: 10.3390/ijms21072277. View

Nordestgaard B, Nicholls S, Langsted A, Ray K, Tybjaerg-Hansen A . Advances in lipid-lowering therapy through gene-silencing technologies. Nat Rev Cardiol. 2018; 15(5):261-272. DOI: 10.1038/nrcardio.2018.3. View

Gouni-Berthold I, Schwarz J, Berthold H . Updates in Drug Treatment of Severe Hypertriglyceridemia. Curr Atheroscler Rep. 2023; 25(10):701-709. PMC: 10564803. DOI: 10.1007/s11883-023-01140-z. View

During A . Osteoporosis: A role for lipids. Biochimie. 2020; 178:49-55. DOI: 10.1016/j.biochi.2020.08.004. View

Miyanishi K, Yamamoto T, Irisa T, Yamashita A, Jingushi S, Noguchi Y . Bone marrow fat cell enlargement and a rise in intraosseous pressure in steroid-treated rabbits with osteonecrosis. Bone. 2002; 30(1):185-90. DOI: 10.1016/s8756-3282(01)00663-9. View

Wang C, McConathy W, Kloer H, Alaupovic P . Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest. 1985; 75(2):384-90. PMC: 423500. DOI: 10.1172/JCI111711. View

Ayers C, Kansagara D, Lazur B, Fu R, Kwon A, Harrod C . Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians. Ann Intern Med. 2023; 176(2):182-195. DOI: 10.7326/M22-0684. View

10.

Akoumianakis I, Zvintzou E, Kypreos K, Filippatos T . ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets. Curr Atheroscler Rep. 2021; 23(5):20. DOI: 10.1007/s11883-021-00914-7. View

11.

Tall A, Thomas D, Gonzalez-Cabodevilla A, Goldberg I . Addressing dyslipidemic risk beyond LDL-cholesterol. J Clin Invest. 2022; 132(1. PMC: 8718149. DOI: 10.1172/JCI148559. View

12.

Song Y, Liu J, Zhao K, Gao L, Zhao J . Cholesterol-induced toxicity: An integrated view of the role of cholesterol in multiple diseases. Cell Metab. 2021; 33(10):1911-1925. DOI: 10.1016/j.cmet.2021.09.001. View

13.

Rizzo M, Rini G . Statins, fracture risk, and bone remodeling: What is true?. Am J Med Sci. 2006; 332(2):55-60. DOI: 10.1097/00000441-200608000-00001. View

14.

Davies N, Holmes M, Davey Smith G . Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018; 362:k601. PMC: 6041728. DOI: 10.1136/bmj.k601. View

15.

Kim H, Oh B, Park-Min K . Regulation of Osteoclast Differentiation and Activity by Lipid Metabolism. Cells. 2021; 10(1). PMC: 7825801. DOI: 10.3390/cells10010089. View

16.

Tian L, Yu X . Fat, Sugar, and Bone Health: A Complex Relationship. Nutrients. 2017; 9(5). PMC: 5452236. DOI: 10.3390/nu9050506. View

17.

Zeng X, Zhan K, Zhang L, Zeng D, Yu W, Zhang X . The impact of high total cholesterol and high low-density lipoprotein on avascular necrosis of the femoral head in low-energy femoral neck fractures. J Orthop Surg Res. 2017; 12(1):30. PMC: 5316144. DOI: 10.1186/s13018-017-0532-0. View

18.

Burgess S, Thompson S . Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017; 32(5):377-389. PMC: 5506233. DOI: 10.1007/s10654-017-0255-x. View

19.

An T, Hao J, Sun S, Li R, Yang M, Cheng G . Efficacy of statins for osteoporosis: a systematic review and meta-analysis. Osteoporos Int. 2016; 28(1):47-57. DOI: 10.1007/s00198-016-3844-8. View

20.

Aleidi S, Al-Ansari M, Alnehmi E, Malkawi A, Alodaib A, Alshaker M . Lipidomics Profiling of Patients with Low Bone Mineral Density (LBMD). Int J Mol Sci. 2022; 23(19). PMC: 9570421. DOI: 10.3390/ijms231912017. View